US FDA/CFSAN - BSE and Cosmetics: FDA Risk Assessment and Management Perspectives - Slide 39

US FDA/CFSAN - BSE and Cosmetics: FDA Risk Assessment and Management Perspectives December 7, 2006

US FDA/CFSAN

BSE and Cosmetics: FDA Risk Assessment and Management Perspectives

December 7, 2006

BSE Risk Assessment-1

Hazard Characterization
- asymptomatic lag period (6 mo. - 4 yr.)
- Associative PrP^c → PrP^res conversion in CNS tissue (exponential concentration increase)
- Dose/Response experimental infectivity in cattle
- Species Barrier in Humans of 10¹-10⁴ needed to cause illness compared with cattle

Slide 39 of 45

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

Slide 39 of 45